Fundraising Fox

Gemini Therapeutics

Cambridge, US · Founded 2015 · Delaware corporation · 3 known investors

Find your way into Gemini Therapeutics

682 people in our graph share verified history with the Gemini Therapeutics team — schools, employers, funds. One of them is your warm intro.

Kyle Dohertyunlockedknows James McLaughlin · together at Harvard Business School (overlapped)
×4knows the team · via Harvard Business School
×3knows the team · via Colby College
×4knows the team · via Third Rock Ventures
Biotech

Founders & leadership

JMJames McLaughlin
James McLaughlininExecutiveJames McLaughlin founded Gemini Therapeutics, a precision medicine company addressing age-related macular degeneration, which he grew through R&D, financing, and team building before co-founding Saturn Therapeutics. He previously co-founded Voyager Therapeutics, a CNS-focused gene therapy company where he led operations, and worked as a biotechnology investor at Third Rock Ventures and Advanced Technology Ventures; he holds an MBA from Harvard Business School and a BA from Colby College.

Board

JGJean George
Jean GeorgeBoard directorManaging Partner at Lightstone Ventures
JRJason Rhodes
Jason RhodesinBoard directorPartner at Atlas Venture
CGCarl Gordon
Carl GordoninBoard directorManaging Partner at OrbiMed

Investors · 3

Lightstone VenturesPortola Valley
Atlas VenturereportedCambridge · $500K – $1M
OrbiMedreported · 2 sourcesNew York · $1M – $75Mvia Carl Gordon · board

Reported raises · per SEC filings

Form D private placements

$2M disclosed across 1 round · 2016

▶$2MraisedMay 2016 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jean GeorgeDirector
  • James McLaughlinExecutive Officer, Director
  • Jason RhodesDirector
  • Carl GordonDirector
Offering amount
$2M
Amount sold
$2M
First sale
Apr 2016
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Disc inks Gemini merger, secures cash from starry VC syndicate to advance ex-AbbVie, Roche drugsfiercebiotech.com · Aug 2022What’s a SPAC? A Route to Public Markets for Gemini Therapeutics | Ophthalmology Innovation Sourceois.net · Mar 2021Gemini Therapeutics and Avitide Enter Into Exclusive License Agreementprnewswire.com · Dec 2019Gemini Therapeutics closes $42.5M Series A for dry age-related macular degeneration therapy - MedCity Newsmedcitynews.com · Oct 2017Gemini Therapeutics Banks $42.5M to Bring Precision Med to AMD - BioSpacebiospace.com · Oct 2017

Frequently asked questions

Who are Gemini Therapeutics's investors?
Gemini Therapeutics's investors include Lightstone Ventures, Atlas Venture, OrbiMed.
How much funding has Gemini Therapeutics raised?
Gemini Therapeutics has disclosed $2M raised across 1 round.
Where is Gemini Therapeutics headquartered?
Gemini Therapeutics is headquartered in Cambridge, US.